Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment Conference In New York
Biomark Diagnostics to Showcase Innovative Liquid Biopsy Technology at H.C. Wainwright’s 26th Annual Global Investment conference in New York Vancouver, British Columbia – (August 26, 2024) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that Chief Executive Officer […]
The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY
The U.S. Patent and Trademark Office Grants BIOMARK PATENT THAT EXPANDS ITS CLAIMS COVERING ITS LEGACY LIQUID BIOPSY ASSAY The new patent granted by the USPTO strengthens and expands BioMark’s global IP portfolio in liquid biopsy, enhancing cancer management solutions. Vancouver, British Columbia – (July 31, 2024) – BioMark Diagnostics Inc., (“BioMark” or the “Company”) […]
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research AT 2024 GPEN Conference
BioMark Diagnostics Announces Presentation of Promising Glioblastoma Research At 2024 GPEN Conference Vancouver, British Columbia – (July 15, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early detection of hard-to-detect and treat cancers, is pleased to announce today that long […]
A Day To Honour Dr. Daniel Sitar: Fellowship of the Society of Pharmacology and Therapeutics
Today is a day to honour Dr Daniel Sitar: Fellowship Canadian Society of Pharmacology and Therapeutics Daniel Sitar BScPharm, MSc, PhD, FGSA,FCP, Professor Emeritus, Rady Faculty of Health Sciences – College of Medicine (Departments of Internal Medicine, Pharmacology and Therapeutics, Pediatrics and Child Health), College of Pharmacy, and Centre on Aging, University ofManitoba. Dr. Sitar […]
BIOMARK Announces Warrant Extension and Granting of Options
BIOMARK Announces Warrant Extension and Granting of Options Vancouver, British Columbia – (April 18th, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce that the Company intends to amend […]
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA
BIOMARK TO ADVANCE DEVELOPMENT OF CANCER TREATMENT FOR GLIOBLASTOMA The Company secured collaborative research funding from Research Manitoba and Mitacs for an animal proof-of-concept study. Vancouver, British Columbia – (April 9, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus […]
BIOMARK PartnerS with RUBIX LS to Advance Blood-based Cancer Screening in Underserved Communities
Vancouver, British Columbia – (February 28, 2024) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic […]
Theresa Peterson Joins BioMark’s Advisory Team
Vancouver, British Columbia – (February 26, 2024) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCMKTS: BMKDF) an advanced-stage liquid biopsy company with a focus on hard-to-detect and treat cancers is pleased to announce that Mrs. Theresa Peterson as a new member of BioMark’s Advisory team. Mr. Rashid Ahmed Bux, CEO and President of […]
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT
BIOMARK ANNOUNCES CLOSING OF $1.9 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia – (December 29th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today that it has closed […]
insightscare Interview: BioMark Diagnostics Inc: Innovating Cancer Detection
BioMark Diagnostics Inc: Innovating Cancer Detection From the interview originally published by insightscare https://insightscare.com/biomark-diagnostics-inc-innovating-cancer-detection/ Rashid A Bux | CEO and Founder | BioMark Diagnostics Inc A dynamic field like diagnostics requires efficient technologies for detecting diseases and critical illnesses. One organization that stands out with its innovative solutions in pursuit of this universal mission is BioMark […]